A scientific approach to anti-ageing therapies: State of the art

Current Pharmaceutical Design

Volumn 14, Issue 26, 2008, Pages 2637-2642

  Jirillo, E ^a,b   Candore, G ^c   Magrone, T ^a   Caruso, C ^c  

^a UNIVERSITY OF BARI   (Italy)

^b National Institute of Gastroenterology   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Ageing; Alzheimer's disease; Cardiovascular ciseases; Diet; Immunosenescence

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ARACHIDONATE 5 LIPOXYGENASE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; POLYPHENOL DERIVATIVE; PROSTAGLANDIN SYNTHASE; PROTEIN P53; TOLL LIKE RECEPTOR 4; ZINC;

AGING; ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; DEMENTIA; DIET THERAPY; DISEASE MARKER; DISEASE PREDISPOSITION; DRUG MECHANISM; GERIATRIC CARE; GERIATRIC DISORDER; HUMAN; IMMUNOCOMPETENCE; INFECTION; INFLAMMATORY DISEASE; LIFE EXPECTANCY; LIFESPAN; NONHUMAN; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; RED WINE; REJUVENATION; REVIEW; SENESCENCE;

AGING; ALZHEIMER DISEASE; CARDIOVASCULAR DISEASES; DIET; HUMANS; IMMUNE SYSTEM;

EID: 57349196012     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786264070     Document Type: Review

References (54)

1. Hayflick L. Biological aging is no longer an unsolved problem. Ann N Y Acad Sci 2007; 1100: 1-13.
2. Kirkwood TBL, Austad SN. Why do we age? Nature 2000; 408: 233-8.
3. Candore G, Colonna-Romano G, Balistreri CR, Di Carlo D, Grimaldi MP, Listì F, et al. Biology of longevity: Role of the innate immune system. Rejuven Res 2006; 9: 143-8.
4. Candore G, Balistreri CR, Colonna-Romano G, Grimaldi MP, Lio D, Listi' F, et al. Immunosenescence and anti-immunosenescence therapies: the case of probiotics Immunosenescence and anti-immunosenescence therapies: The case of probiotics. Rejuvenation Res 2008; 11: 425-32.
5. Capri M, Monti D, Salvioli S, Lescai F, Pierini M, Altilia S, et al. Complexity of anti-immunosenescence strategies in humans. Artif Organs 2006; 30: 730-42.
6. Henson SM, Macaulay R, Kiani-Alikahn S, Akbar AN. The use of the inhibitory receptors for modulating the immune responses. Curr Pharm Des 2008; 14(26): 2643-50.
7. Vasto S, Candore G, Listì F, Balistreri CR, Colonna-Romano G, Malavolta M, et al. Inflammation, Genes and Zinc in Alzheimer's disease. Brain Res Rev 2008, 58: 96-105.
8. Vasto S, Candore G, Duro G, Lio D, Grimaldi MP, Caruso C. Alzheimer's disease and genetics of inflammation: A pharmacogenomic vision. Pharmacogenomics 2007; 8: 1735-45.
9. Racchi M, Uberti D, Govoni S, Memo M, Lanni C, Vasto S, et al. Alzheimer's disease: New diagnostic and therapeutic tools. Immun Ageing 2008; 5:7.
10. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605-13.
11. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, et al. The role of biomarkers in clinical trials for Alzheimer's disease. Alzheimer Dis Assoc Disord 2006; 20: 6-15.
12. Godbout JP, Johnson RW. Age and neuroinflammation: A lifetime of psychoneuroimmune consequences. Neurol Clin 2006; 24: 521-38.
13. Calabrese V, Stella AM, Butterfield DA, Scapagnini G. Redox regulation in neurodegeneration and longevity: Role of the heme oxygenase and HSP70 systems in brain stress tolerance. Antioxid Redox Signal 2004; 6: 895-913.
14. Amadio M, Scapagnini G, Laforenza U, Intrieri, M, Romeo L, Govoni S, et al. Post-transcriptional regulation of HSP70 expression following oxidative stress in SH-SY5Y cells: The potential involvement of the RNA-binding protein HuR. Curr Pharm Des 2008; 14(26): 2651-8.
15. Porcellini E, Davis EJ, Chiappelli M, Ianni E, Di Stefano G, Forti P, et al. Elevated plasma levels of α-1-anti-chymotrypsin in age-related cognitive decline and Alzheimer's disease: A potential therapeutic target. Curr Pharm Des 2008; 14(26): 2659-64.
16. Abraham CR. Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease. Neurobiol Aging 2001; 22: 931-6.
17. Styren SD, Kamboh MI, DeKosky ST. Expression of differential immune factors in temporal cortex and cerebellum: The role of alpha-1-antichymotrypsin, apolipoprotein E, and reactive glia in the progression of Alzheimer's disease. J Comp Neurol 1998; 396: 511-20.
18. Eriksson S, Janciauskiene S, Lannfelt L. α1-antichymotrypsin regulates Alzheimer β-amyloid peptide fibril formation. Proc Natl Acad Sci USA 1995; 92: 2313-7.
19. Fraser PE, Nguyen JT, McLachlan DR, Abraham CR, Kirschner DA. α1-antichymotrypsin binding to Alzheimer's Aβ peptides is sequence specific and induces fibril disaggregation in vitro. J Neurochem 1993; 61: 298-305.
20. Lanni C, Racchi M, Uberti D, Mazzini G, Stanga S, Sinforiani E, et al. Pharmacogenenetics and pharmacogenomics, trends in normal and pathological ageing studies: Focus on p53. Curr Pharm Des 2008; 14(26): 2665-71.
21. Rodier F, Campisi J, Bhaumik D. Two faces of p53: Aging and tumor suppression. Nucleic Acids Res 2007; 35: 7475-84.
22. Balistreri CR, Candore G, Listi' F, Fazio T, Gangi S, Incalcaterra E, et al. Role of TLR4 polymorphisms in inflammatory responses implications for unsuccessful aging. Ann N Y Acad Sci 2007; 1119: 203-7.
23. Balistreri CR, Grimaldi MP, Chiappelli M, Licastro F, Castiglia L, Listi F, et al. Association between the polymorphisms of TLR4 and CD14 genes and Alzheimer's disease. Curr Pharm Des 2008; 14 (26): 2672-7.
24. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflamm 2008; 5: 2.
25. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: A 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002; 52: 168-74.
26. Candore G, Balistreri CR, Caruso M, Grimaldi MP, Incalcaterra E, Listì F, et al. Pharmacogenomics: A tool to prevent and cure coronary heart disease. Curr Pharm Des 2007; 13: 3726-34.
27. Caruso C, Balistreri CR, Crivello A, Forte GI, Grimaldi MP. Listì F, et al. The genetics of innate immunity and inflammation in ageing, age-related diseases and longevity. Immunosenescence. Pawelec, Austin, TX, USA, 2007; 154-73.
28. Listì F, Caruso M, Incalcaterra E, Hoffmann E, Caimi G, Balistreri CR, et al. Pro-inflammatory gene variants in myocardial infarction and longevity: Implications for pharmacogenomics. Curr Pharm Des 2008; 14(26): 2678-85.
29. Franklyn JA. Subclinical thyroid disorders-consequences and implications for treatment. Ann Endocrinol (Paris) 2007; 68: 229-30.
30. Iacoviello M, Guida P, Guastamacchia E, Triggiani V, Forleo C, Catanzaro R, et al. Prognostic role of sub-clinical hypothyroidism in chronic heart failure outpatients. Curr Pharm Des 2008; 14(26): 2686-92.
31. Hotamisligil, GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
32. Rocchini AP. Childhood obesity and a diabetes epidemic. N Engl J Med 2002; 346: 854-5.
33. Chiloiro M, Riezzo G, Chiarappa S, Correale M, Guerra V, Amati L, et al. Relationship among fatty liver, adipose tissue distribution and metabolic profile in moderately obese children: An ultrasonographic study. Curr Pharm Des 2008; 14(26): 2693-8.
34. Di Renzo L, Bertoli A, Bigioni M, Del Gobbo V, Premrov MG, Calabrese V, et al. Body composition and -174G/C interleukin-6 promoter gene polymorphism: Association with progression of insulin resistance in normal weight obese syndrome. Curr Pharm Des 2008; 14(26): 2699-706.
35. Candore G, Vasto S, Colonna-Romano G, Lio D, Caruso M, Rea IM, et al. Atherosclerosis. In: Cytokine Gene Polymorphisms in Multifactorial Conditions. Vandenbroeck, Boca Raton, FL, USA. 2006; 363-78.
36. Rea IM, Candore G, Cavallone L, Olivieri F, Cardelli M, Franceschi C, et al. Longevity. In: Cytokine Gene Polymorphisms In Multifactorial Conditions. Vandenbroeck, Boca Raton, FL, USA. 2006; 379-94.
37. Alvarez-Leon EE, Roman-Vinas B, Serra-Majem L. Dairy products and health: A review of the epidemiological evidence. Br J Nutr 2006; 96: S94-S99.
38. Ames BN. Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage. Proc Natl Acad Sci USA 2006; 103: 17589-94.
39. Kant AK. Consumption of energy-dense, nutrient-poor foods by adult Americans: Nutritional and health implications. The third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2000; 72: 929-36.
40. Semba RD, Bartali B, Zhou J, Blaum C, Ko CW. Fried LP. Low serum micronutrient concentrations predict frailty among older women living in the community. J Gerontol A Biol Sci Med Sci 2006; 61: 594-9.
41. Trosko JE. Role of diet and nutrition on the alteration of the quality and quantity of stem cells in human aging and the diseases of aging. Curr Pharm Des 2008; 14(26): 2707-18.
42. Giacconi R, Caruso C, Malavolta M, Lio D, Balistreri CR, Scola L, et al. Pro-inflammatory genetic background and zinc status in old atherosclerotic subjects. Ageing Res Rev 2008 (in press). doi:101016/ jarr200806001
43. Mocchegiani E, Malavolta M, Muti E, Costarelli L, Cipriano C, Piacenza F, et al. Zinc, Metallothioneins and longevity: Inter-relationship with niacin and selenium. Curr Pharm Des 2008; 14(26): 2719-32.
44. Trichopoulou A, Dilis V. Olive oil and longevity. Mol Nutr Food Res 2007; 51: 1275-8.
45. Magrone T, Candore G, Caruso G, Jirillo E, Covelli V. Polyphenols from red wine modulate immune responsiveness: Biological and clinical significance. Curr Pharm Des 2008; 14(26): 2733-48.
46. Magrone T, Tafaro A, Jirillo F, Amati L, Jirillo E, Covelli V. Elicitation of immune responsiveness against antigenic challenge in age-related diseases: Effects of red wine polyphenols. Curr Pharm Des 2008; 14(26): 2749-57.
47. Magrone T, Panaro MA, Jirillo E, Covelli V. Molecular effects elicited in vitro by red wine on human healthy peripheral blood mononuclear cells. Potential therapeutical application of polyphenols to diet-related chronic diseases. Curr Pharm Des 2008; 14(26): 2758-66.
48. Bradamante S, Barenghi L, Piccinini F, Bertelli AA, De Jonge R, Beemster P, et al. Resveratrol provides late-phase cardioprotetion by means of a nitric oxide and and adenosine-mediated mechanism. Eur J Pharmacol 2003; 465: 115-23.
49. Das S, Fraga CG, Das DK. Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI-3-kinase signaling, but does not involve NF-κB. Free Rad Res 2006; 40: 1066-75.
50. Shen MY, Hsiao G, Liu CL, Fong TH, Lin KH, Chou DS, et al. Inhibitory mechanisms of resveratrol in platelet activation: Pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol 2007; 139: 475-85.
51. De Grey A. Ending Aging. St. Martin's press, New York, NY, USA 2007.
52. Cuadrado A, Rojo AI. Heme oxygenase-1 as a therapeutic target in neurodegenerative diseases and brain infections. Curr Pharm Des 2008; 14(5): 429-42.
53. Potterat O, Hamburger M. Drug discovery and development with plant-derived compounds. Prog Drug Res 2008; 65: 47-118.
54. Shiba Y, Takahashi M, Ikeda U. Models for the study of angio-genesis. Curr Pharm Des 2008; 14(4): 371-7.